• Explore /
  • Poster
  • / MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and mFOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer—Trial in progress.

Abstract Poster

Authors

Tanios Bekaii-Saab

Tanios S. Bekaii-Saab

Mayo Clinic, Scottsdale, AZ;

Tanios S. Bekaii-Saab , Eric Van Cutsem , Josep Tabernero , Salvatore Siena , Takayuki Yoshino , Yoshiaki Nakamura , Kanwal Pratap Singh Raghav , Andrea Cercek , Volker Heinemann , David E. Adelberg , James Edward Ward , Shan Yang , Thierry Andre , John H Strickler

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05253651

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS261)

DOI

10.1200/JCO.2023.41.4_suppl.TPS261

Abstract #

TPS261

Poster Bd #

P3

Abstract Disclosures

Similar Posters

First Author: Tanios S. Bekaii-Saab

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.

First Author: Luis A. Diaz Jr.